QNCX · Quince Therapeutics, Inc.
$31.73
+2.37 (+8.07%)
At close · Oct 9
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Factoring in these potential cash payments, based on its current operating plan, the Company believes that its cash and cash equivalents balance will not be sufficient to fund operations and capital expenditures for at least the twelve months following the issuance of these unaudited condensed consolidated financial statements. Accordingly, the Company concluded that substantial doubt about the Company's ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$32.27M
Shares
1.02M
Volume · Oct 9
138.74K
Avg daily vol (3M)
30.54K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$31.73
Open$30.50
Day$29.84–37.00
52W close$16.00–880.00
Avg vol 30d27K
Short int60K · 5.9% float · 2.7d
Short vol41%
Last earningsAug 13, 2024
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$92.48M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-145.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2,527.3%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.9%
Latest settlement · 2.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−68%
below
Price vs 50-day avg
+4%
above
RSI (14)
57
neutral
MACD trend
Negative
52-week position
2%
near low
Momentum
relative strength
1-month return
+7%
trailing
6-month return
+25%
trailing
YTD return
−95%
this year
Relative strength
+15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $30 › 200d $99 — 200d above 50d
Institutional flow
Distributing
-42% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.89% of float · ▲ +19.2% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
28 holders — near 3-yr low, contrarian setup
Squeeze score
74
high risk · 0–100
Fundamentals
EPS growth
−28%
Y/Y
Free cash flow
$-41.8M
Balance sheet
$5.8M
net cash
Quant / Vol
risk profile
Volatility
356%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
8.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jan 30, 2023
Estimated annualized operating expense savings
· year ending December 31, 2023 (excluding share-based compensatio
$9.5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−68%
Bearish
Price vs 50-day avg
+4%
Bullish
RSI (14)
57
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $30 › 200d $99 — 200d above 50d
Institutional flow
Distributing
-42% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.89% of float · ▲ +19.2% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
28 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $16
Now $32 · 2%
Range high $880
vs 200-day avg -68%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QNCX
this stock
Quince Therapeutics, Inc.
|
$32.27M | — | — | — | 5.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.77B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QNCX | +8.7% | +7.4% | +24.9% | +2.3% | -95.3% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | +7.5% | +5.5% | +15.1% | +0.2% | -109.4% |